Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
Financial Results:
Concord Biotech Ltd reported Revenues for Q2FY25 of ₹310.00 Crores up from ₹262.00 Crore year on year, a rise of 18.32%.
Total Expenses for Q2FY25 of ₹189.00 Crores up from ₹161.00 Crores year on year, a rise of 17.39%.
Consolidated Net Profit of ₹96.00 Crores up 18.52% from ₹81.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹9.15, up 18.22% from ₹7.74 in the same quarter of the previous year.